Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study

Richard S. Finn, Carmelo Bengala, Nuhad Ibrahim, Henri Roche, Joseph A. Sparano, Lewis C. Strauss, Justin Fairchild, Oumar Sy, Lori J. Goldstein

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Purpose: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-negative, or basal-like, breast cancer cell lines. This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-negative breast cancer (TNBC). Experimental Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID. Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics. Results: Of the 44 treated patients, 43 were response evaluable. ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 weeks, respectively. Of 11 patients with stable disease, two continued for more than 16 weeks, thus protocol-defined DCR was 9.3%. Median PFS was 8.3 weeks (95% CI: 7.3-15.3). Five patients discontinued before first tumor assessment. No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%). Laboratory abnormalities were uncommon. Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose reduction, and serious AEs were lower with dasatinib 70 mg BID. Conclusions: Single-agent dasatinib has limited activity in unselected patients with TNBC. Dasatinib 70 mg BID was better tolerated than 100 mg BID. Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.

Original languageEnglish (US)
Pages (from-to)6905-6913
Number of pages9
JournalClinical Cancer Research
Volume17
Issue number21
DOIs
StatePublished - Nov 1 2011

Fingerprint

Triple Negative Breast Neoplasms
Disease-Free Survival
Breast Neoplasms
Safety
Dasatinib
Pleural Effusion
Combination Drug Therapy
Dyspnea
Fatigue
Diarrhea
Research Design
Phosphotransferases
Pharmacokinetics
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dasatinib as a single agent in triple-negative breast cancer : Results of an open-label phase 2 study. / Finn, Richard S.; Bengala, Carmelo; Ibrahim, Nuhad; Roche, Henri; Sparano, Joseph A.; Strauss, Lewis C.; Fairchild, Justin; Sy, Oumar; Goldstein, Lori J.

In: Clinical Cancer Research, Vol. 17, No. 21, 01.11.2011, p. 6905-6913.

Research output: Contribution to journalArticle

Finn, RS, Bengala, C, Ibrahim, N, Roche, H, Sparano, JA, Strauss, LC, Fairchild, J, Sy, O & Goldstein, LJ 2011, 'Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study', Clinical Cancer Research, vol. 17, no. 21, pp. 6905-6913. https://doi.org/10.1158/1078-0432.CCR-11-0288
Finn, Richard S. ; Bengala, Carmelo ; Ibrahim, Nuhad ; Roche, Henri ; Sparano, Joseph A. ; Strauss, Lewis C. ; Fairchild, Justin ; Sy, Oumar ; Goldstein, Lori J. / Dasatinib as a single agent in triple-negative breast cancer : Results of an open-label phase 2 study. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 21. pp. 6905-6913.
@article{58d81df14f68460887516e8a3ac5f330,
title = "Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study",
abstract = "Purpose: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-negative, or basal-like, breast cancer cell lines. This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-negative breast cancer (TNBC). Experimental Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID. Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics. Results: Of the 44 treated patients, 43 were response evaluable. ORR was 4.7{\%}: two patients had confirmed partial responses lasting 14 and 58 weeks, respectively. Of 11 patients with stable disease, two continued for more than 16 weeks, thus protocol-defined DCR was 9.3{\%}. Median PFS was 8.3 weeks (95{\%} CI: 7.3-15.3). Five patients discontinued before first tumor assessment. No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5{\%} of patients were fatigue (9.1{\%}), diarrhea, pleural effusion, and dyspnea (all 6.8{\%}). Laboratory abnormalities were uncommon. Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose reduction, and serious AEs were lower with dasatinib 70 mg BID. Conclusions: Single-agent dasatinib has limited activity in unselected patients with TNBC. Dasatinib 70 mg BID was better tolerated than 100 mg BID. Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.",
author = "Finn, {Richard S.} and Carmelo Bengala and Nuhad Ibrahim and Henri Roche and Sparano, {Joseph A.} and Strauss, {Lewis C.} and Justin Fairchild and Oumar Sy and Goldstein, {Lori J.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-11-0288",
language = "English (US)",
volume = "17",
pages = "6905--6913",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Dasatinib as a single agent in triple-negative breast cancer

T2 - Results of an open-label phase 2 study

AU - Finn, Richard S.

AU - Bengala, Carmelo

AU - Ibrahim, Nuhad

AU - Roche, Henri

AU - Sparano, Joseph A.

AU - Strauss, Lewis C.

AU - Fairchild, Justin

AU - Sy, Oumar

AU - Goldstein, Lori J.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Purpose: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-negative, or basal-like, breast cancer cell lines. This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-negative breast cancer (TNBC). Experimental Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID. Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics. Results: Of the 44 treated patients, 43 were response evaluable. ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 weeks, respectively. Of 11 patients with stable disease, two continued for more than 16 weeks, thus protocol-defined DCR was 9.3%. Median PFS was 8.3 weeks (95% CI: 7.3-15.3). Five patients discontinued before first tumor assessment. No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%). Laboratory abnormalities were uncommon. Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose reduction, and serious AEs were lower with dasatinib 70 mg BID. Conclusions: Single-agent dasatinib has limited activity in unselected patients with TNBC. Dasatinib 70 mg BID was better tolerated than 100 mg BID. Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.

AB - Purpose: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-negative, or basal-like, breast cancer cell lines. This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-negative breast cancer (TNBC). Experimental Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID. Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics. Results: Of the 44 treated patients, 43 were response evaluable. ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 weeks, respectively. Of 11 patients with stable disease, two continued for more than 16 weeks, thus protocol-defined DCR was 9.3%. Median PFS was 8.3 weeks (95% CI: 7.3-15.3). Five patients discontinued before first tumor assessment. No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%). Laboratory abnormalities were uncommon. Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose reduction, and serious AEs were lower with dasatinib 70 mg BID. Conclusions: Single-agent dasatinib has limited activity in unselected patients with TNBC. Dasatinib 70 mg BID was better tolerated than 100 mg BID. Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.

UR - http://www.scopus.com/inward/record.url?scp=80455173400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455173400&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-0288

DO - 10.1158/1078-0432.CCR-11-0288

M3 - Article

C2 - 22028489

AN - SCOPUS:80455173400

VL - 17

SP - 6905

EP - 6913

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -